Literature DB >> 15099912

Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss.

Yosefa Avraham1, Dikla Ben-Shushan, Aviva Breuer, Olga Zolotarev, Avital Okon, Nir Fink, Vered Katz, Elliot M Berry.   

Abstract

We have investigated the effect of 0.001 mg/kg delta(8)-tetrahydrocannabinol (THC) on food consumption, cognitive function, and neurotransmitters in mice. Sabra mice were treated with vehicle, THC, or THC+CB1 antagonist (SR141716A). The mice were fed for 2.5 h a day for 9 or 50 days. In the 9-day schedule, THC-treated mice showed a 16% increase in food intake compared with controls (P<.001). This effect was reversed by the antagonist (P<.01). In the long-term schedule a 22% increase in intake (P<.05) was recorded. During the course of the 9- and 50-day experimental protocol, all mice lost about 20% and 10% of their original weight, respectively, to reach approximately the same weights, which were not significantly different between the different treatment groups. In addition, THC caused an increase in activity (P<.05). Cognitive function showed a tendency to improve (P<.06) in the THC-treated mice, which was reversed by the antagonist for Days 4 and 5 of the maze (P<.01, and P<.05, respectively). Significant decreases in dopamine and serotonin (5-HT) levels were found both in the hypothalamus (P<.01) and the hippocampus (P<.01, P<.05), respectively, while norepinephrine (NE) levels showed tendency to increase in both the hypothalamus and hippocampus. Delta(8)-THC increased food intake significantly more (P<.05) than did delta(9)-THC, while performance and activity were similar. Thus, delta(8)-THC (0.001 mg/kg) caused increased food consumption and tendency to improve cognitive function, without cannabimimetic side effects. Hence, a low dose of THC might be a potential therapeutic agent in the treatment of weight disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099912     DOI: 10.1016/j.pbb.2004.01.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Authors:  Ketan Hippalgaonkar; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

Review 2.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

3.  CB1 cannabinoid receptor-mediated modulation of food intake in mice.

Authors:  Jenny L Wiley; James J Burston; Darnica C Leggett; Olga O Alekseeva; Raj K Razdan; Anu Mahadevan; Billy R Martin
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

4.  Constituents of Cannabis Sativa.

Authors:  Erin M Rock; Linda A Parker
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Cannabinoids in eating disorders and obesity.

Authors:  Francisco Arias Horcajadas
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

Review 6.  Cannabinoids as therapeutic agents in cancer: current status and future implications.

Authors:  Bandana Chakravarti; Janani Ravi; Ramesh K Ganju
Journal:  Oncotarget       Date:  2014-08-15

7.  Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism.

Authors:  Chung Thong Lim; Blerina Kola; Daniel Feltrin; Diego Perez-Tilve; Matthias H Tschöp; Ashley B Grossman; Márta Korbonits
Journal:  Mol Cell Endocrinol       Date:  2012-11-20       Impact factor: 4.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.